Key points are not available for this paper at this time.
AIM: Gold standard as material in vital pulp therapy (VPT) is hydraulic calcium silicate cements (HCSC). To circumvent their prolonged setting time, light-cured pulp capping materials containing calcium silicate or calcium hydroxide powder are available. Although their positive biological properties are advertised, the data regarding the biocompatibility of light-cured pulp capping materials (LCPCM) is inconclusive. This in vitro study compared the biocompatibility of five LCPCM containing calcium silicate (TheraCal LC, ReviCal, MTA PulpCap, Pulprotec MTA) or calcium hydroxide (Calcimol LC) with that of the HCSC Biodentine. METHODS: colorimetric assay) and the mineralisation capacity of the cells (Alizarin Red S Staining, Alkaline Phosphatase Assay) were determined. Statistical analysis was performed by anova and the post-hoc Tukey test (p < 0.05). RESULTS: Compared to Biodentine, hDPC showed significantly lower cell viability when in contact with LCPCM (p < 0.05). Further, an inhibition zone around the test bodies or an altered cell morphology was observed. Biodentine showed almost no negative effects on cell viability or cell morphology. In contact with Biodentine, hDPC mineralise with and without mineralisation induction conditions. Among the LCPCM, mineralisation was only detectable under induction conditions with ReViCal and MTA PulpCap. In addition, Biodentine released significantly more calcium ions than the LCPCM (p < 0.05). CONCLUSION: In this in vitro study, LCPCM showed cytotoxic effects on hDPC and were hardly able to induce cell mineralisation. Biodentine showed little negative effects on cell viability, induced cell mineralisation and released more calcium than LCPCM. Biodentine is significantly superior to LCPCM in terms of biocompatibility and mineralisation induction capacity.
Laurentia et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: